Rivaroxaban vs. warfarin on extended deep venous thromboembolism treatment: A cost analysis. [electronic resource]
Producer: 20180828Description: 53-59 p. digitalISSN:- 1758-1125
- Adult
- Aged
- Ambulatory Care -- economics
- Anticoagulants -- adverse effects
- Blood Coagulation -- drug effects
- Cost Savings
- Cost-Benefit Analysis
- Drug Costs
- Drug Monitoring -- economics
- Factor Xa Inhibitors -- adverse effects
- Female
- Health Care Costs
- Hemorrhage -- chemically induced
- Hospital Costs
- Humans
- International Normalized Ratio -- economics
- Male
- Middle Aged
- Models, Economic
- Retrospective Studies
- Risk Factors
- Rivaroxaban -- adverse effects
- Thromboembolism -- blood
- Time Factors
- Treatment Outcome
- Venous Thrombosis -- blood
- Warfarin -- adverse effects
No physical items for this record
Publication Type: Comparative Study; Journal Article
There are no comments on this title.
Log in to your account to post a comment.